Home » The Medicines Company Submits Angiomax (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
The Medicines Company Submits Angiomax (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
The Medicines Company announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Angiomax (bivalirudin) in support of a proposed new dosage for immediate treatment of patients with acute coronary syndromes (ACS).
Business Wire
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May